Diltiazem (Cardizem)

Diltiazem, commonly known by the brand name Cardizem, is a calcium channel blocker belonging to the benzothiazepine class of cardiovascular medications. In equine medicine, diltiazem serves as an important therapeutic option for managing various cardiac arrhythmias, particularly supraventricular tachyarrhythmias and atrial fibrillation. While originally developed for human use, this medication has found significant application in equine cardiology due to its effectiveness in controlling heart rate and restoring normal cardiac rhythm in horses experiencing specific types of heart rhythm disturbances.

The mechanism of action of diltiazem involves blocking L-type calcium channels in cardiac muscle cells and vascular smooth muscle. By inhibiting calcium influx through these channels, the medication slows electrical conduction through the atrioventricular node, which is particularly beneficial in managing supraventricular arrhythmias. In horses, this action helps reduce the ventricular response rate during atrial fibrillation and can facilitate conversion to normal sinus rhythm in some cases. The drug also produces mild vasodilation, which can reduce cardiac workload and improve overall cardiovascular function.

Diltiazem is available in multiple formulations including injectable solutions for intravenous administration and oral tablets or extended-release capsules for maintenance therapy. In emergency or hospital settings, intravenous diltiazem allows for rapid onset of action and precise dose titration, making it valuable for acute management of cardiac arrhythmias. Oral formulations may be used for longer-term rate control in horses with chronic atrial fibrillation that are not candidates for cardioversion or in cases where the arrhythmia has recurred following initial treatment.

The safety profile of diltiazem in horses requires careful consideration due to its potent effects on cardiac function. This medication should only be administered under direct veterinary supervision, ideally by a veterinarian with experience in equine cardiology. Continuous electrocardiographic monitoring is essential during intravenous administration to detect any adverse cardiac effects. Proper patient selection, accurate dosing based on body weight, and appropriate monitoring protocols are critical for safe and effective use of diltiazem in equine patients with cardiac arrhythmias.

The primary indication for diltiazem in equine medicine is the management of supraventricular tachyarrhythmias, with atrial fibrillation being the most common condition treated. Atrial fibrillation is the most frequently diagnosed cardiac arrhythmia in horses, particularly affecting performance horses and those engaged in strenuous athletic activities. This condition occurs when the atria of the heart beat in a chaotic, disorganized manner, leading to an irregular and often rapid ventricular response that can significantly impact exercise tolerance and performance. Diltiazem serves as a valuable tool for controlling ventricular rate and, in some cases, facilitating cardioversion to normal sinus rhythm.

In horses with atrial fibrillation, diltiazem is often used as part of a rate control strategy, particularly when the primary goal is to slow the ventricular response rate rather than convert the rhythm. This approach may be appropriate for horses with long-standing atrial fibrillation, those with underlying structural heart disease, or cases where previous cardioversion attempts have failed. By slowing conduction through the atrioventricular node, diltiazem helps reduce the number of atrial impulses that reach the ventricles, resulting in a more controlled heart rate that can improve the horse's comfort and functional capacity.

Supraventricular tachycardia represents another important indication for diltiazem use in horses. This arrhythmia involves abnormally rapid heart rates originating above the ventricles and can cause significant hemodynamic compromise if sustained. Diltiazem's ability to slow atrioventricular nodal conduction can interrupt the reentrant circuit responsible for many supraventricular tachycardias, potentially terminating the arrhythmia or at least controlling the ventricular rate until more definitive treatment can be implemented.

Veterinarians may also consider diltiazem in the management of horses with multifocal atrial tachycardia or atrial flutter, though these arrhythmias are less common than atrial fibrillation. In some cases, diltiazem may be used in combination with other antiarrhythmic medications to achieve better rhythm or rate control. The decision to use diltiazem for any cardiac arrhythmia should be based on a thorough cardiovascular evaluation including electrocardiography and echocardiography to characterize the arrhythmia and assess underlying cardiac structure and function.

Beyond primary arrhythmia management, diltiazem may occasionally be considered for horses requiring rate control during anesthesia or in critical care settings where tachyarrhythmias develop secondary to other conditions such as systemic inflammatory response, electrolyte imbalances, or pain. In these situations, addressing the underlying cause remains paramount, but diltiazem can provide symptomatic relief and cardiovascular stabilization while the primary condition is being treated.

Dosing protocols for diltiazem in horses must be determined by a qualified veterinarian with expertise in equine cardiology, as this medication requires careful titration and continuous monitoring. The dosing approach varies significantly based on the route of administration, the specific arrhythmia being treated, and the individual patient's response. Accurate body weight determination is essential, and the use of an equine scale rather than weight tape estimation is strongly recommended given the critical nature of cardiac medications and the need for precise dosing.

For acute management of supraventricular arrhythmias, diltiazem is typically administered intravenously in a hospital or referral center setting. Initial dosing usually involves a slow bolus administration with careful monitoring of heart rate and rhythm via continuous electrocardiography. The veterinarian may repeat or adjust dosing based on the observed response, with the goal of achieving adequate rate control without causing excessive bradycardia or hypotension. The total dose and infusion rate must be individualized to each patient, taking into account factors such as the severity of the arrhythmia, underlying cardiac function, and any concurrent medications.

Continuous intravenous infusion may be initiated following successful bolus administration to maintain rate control in horses with persistent arrhythmias. This approach requires hospitalization with constant monitoring and allows for real-time dose adjustments based on the patient's response. The infusion rate is typically started at a conservative level and increased gradually until the desired effect is achieved or adverse effects necessitate dose reduction.

Oral diltiazem may be considered for longer-term rate control in horses with chronic atrial fibrillation, though bioavailability and pharmacokinetics in horses differ from those in humans and other species. Extended-release formulations designed for humans may not release medication appropriately in the equine gastrointestinal tract, so immediate-release tablets are generally preferred. Oral dosing typically requires administration multiple times daily to maintain therapeutic drug levels, and the frequency and total daily dose must be established through careful clinical monitoring and, ideally, therapeutic drug level monitoring.

Administration of intravenous diltiazem requires proper technique and equipment. The medication should be administered slowly over several minutes, with the horse connected to continuous ECG monitoring throughout the procedure. Emergency resuscitation equipment and medications, including calcium gluconate to reverse excessive calcium channel blockade, should be readily available. The horse should remain quiet and unstressed during administration, as excitement or exercise can complicate interpretation of the cardiac response.

If a scheduled oral dose is missed, owners should not attempt to double the next dose, as this could lead to excessive drug levels and potentially dangerous cardiac effects. Instead, the missed dose should be skipped and the regular dosing schedule resumed. Any concerns about missed doses or changes in the horse's condition should prompt immediate communication with the prescribing veterinarian. Long-term therapy requires regular follow-up evaluations including physical examination, electrocardiography, and potentially echocardiography to assess treatment efficacy and detect any adverse effects.

Diltiazem's effects on the cardiovascular system mean that side effects are primarily cardiac in nature, though other organ systems may also be affected. When administered at appropriate doses with proper monitoring, many horses tolerate diltiazem well, but the potential for serious adverse effects necessitates careful observation throughout treatment. Understanding the range of possible side effects helps veterinarians and horse owners recognize problems early and respond appropriately.

The most common and clinically significant side effects involve excessive slowing of heart rate or conduction. Bradycardia, or abnormally slow heart rate, can occur when diltiazem's effect on the atrioventricular node is more pronounced than intended. Mild bradycardia may be acceptable or even desirable in some situations, but severe bradycardia can compromise cardiac output and lead to weakness, lethargy, or collapse. Advanced atrioventricular block, where electrical signals from the atria fail to conduct properly to the ventricles, represents a more serious conduction disturbance that may require immediate intervention including discontinuation of the medication and administration of reversal agents.

Hypotension is another important cardiovascular side effect resulting from diltiazem's vasodilatory properties. While mild vasodilation can be beneficial by reducing cardiac workload, excessive blood pressure reduction can compromise tissue perfusion and cause clinical signs ranging from lethargy to cardiovascular collapse. Horses receiving intravenous diltiazem should have blood pressure monitored, particularly during initial dosing and dose adjustments. Signs of hypotension may include weakness, increased heart rate as a compensatory response, pale mucous membranes, and prolonged capillary refill time.

Gastrointestinal side effects may occur with oral diltiazem administration and can include decreased appetite, mild colic signs, or changes in manure consistency. These effects are generally mild but should be monitored, particularly during initial therapy or dose adjustments. Horses experiencing persistent gastrointestinal upset may require dose modification or alternative treatment approaches.

Neurological signs including sedation, depression, or altered mentation have been reported in some horses receiving diltiazem, though these effects are generally uncommon at therapeutic doses. Any significant changes in behavior or mental status should prompt veterinary evaluation to determine whether they are related to the medication or represent progression of underlying disease. Peripheral edema, particularly of the lower limbs, can occur due to the drug's vasodilatory effects and is usually mild and self-limiting but should be monitored.

Severe or life-threatening side effects are uncommon when diltiazem is used appropriately but can occur. Complete heart block, severe hypotension, and cardiovascular collapse represent medical emergencies requiring immediate intervention. These risks underscore the importance of administering diltiazem only in settings where continuous monitoring and emergency support are available. Any horse showing signs of cardiovascular instability during diltiazem therapy requires immediate veterinary attention.

Several conditions absolutely or relatively contraindicate the use of diltiazem in horses, and thorough cardiovascular evaluation is essential before initiating therapy. Identifying these contraindications helps prevent potentially serious or life-threatening complications and guides selection of alternative treatment approaches when diltiazem is not appropriate.

Pre-existing conduction system disease represents a primary contraindication to diltiazem use. Horses with sick sinus syndrome, second-degree or third-degree atrioventricular block, or other significant conduction abnormalities should not receive diltiazem, as the drug's effects on the atrioventricular node could worsen these conditions and potentially cause complete heart block or cardiac arrest. Thorough electrocardiographic evaluation prior to treatment is essential to identify any underlying conduction abnormalities that might not be clinically apparent.

Severe hypotension contraindicates diltiazem administration due to the drug's additional blood pressure-lowering effects. Horses in shock, those with significant dehydration, or animals with other causes of cardiovascular compromise should not receive diltiazem until these conditions are stabilized. Similarly, horses with severe heart failure, particularly those with significantly reduced cardiac contractility, may not tolerate diltiazem's negative inotropic effects. Comprehensive echocardiographic assessment of cardiac function is important for identifying horses at increased risk for adverse effects.

Known hypersensitivity to diltiazem or other calcium channel blockers precludes use of this medication. Although true allergic reactions are uncommon, any history of adverse reactions to calcium channel blockers should be carefully evaluated before considering diltiazem therapy. Horses with a history of severe reactions should not receive this class of medication.

Concurrent use of other medications that significantly affect cardiac conduction or blood pressure may contraindicate or require extreme caution with diltiazem. Beta-blockers, in particular, can have additive effects with diltiazem on heart rate and conduction, potentially leading to dangerous bradycardia or heart block. Other antiarrhythmic medications, certain anesthetic agents, and drugs affecting calcium metabolism may also interact unfavorably with diltiazem. Complete medication history review is essential before initiating therapy.

Pregnancy represents a relative contraindication, as the effects of diltiazem on equine fetal development have not been well studied. The medication crosses the placenta in other species and could potentially affect fetal cardiac development or function. Use in pregnant mares should only be considered when the potential benefit clearly outweighs the risks and no safer alternatives exist. Similarly, caution is advised in nursing mares due to potential excretion in milk.

Diltiazem has significant potential for drug interactions due to its effects on cardiac conduction, blood pressure, and hepatic metabolism. Awareness of these interactions is critical for safe prescribing and helps prevent potentially dangerous combinations. Veterinarians must obtain a complete medication history before initiating diltiazem therapy and carefully consider potential interactions throughout treatment.

The most clinically significant interactions involve other medications affecting cardiac conduction or contractility. Beta-adrenergic blockers such as propranolol, when combined with diltiazem, can cause additive negative chronotropic and dromotropic effects, potentially leading to severe bradycardia, atrioventricular block, or cardiac arrest. If both drug classes are deemed necessary, extremely careful dose titration and continuous monitoring are required. Other antiarrhythmic medications including digoxin, quinidine, and amiodarone may also interact with diltiazem, requiring dose adjustments and enhanced monitoring when used concurrently.

Digoxin interactions deserve particular attention as both medications may be used in horses with atrial fibrillation. Diltiazem can increase serum digoxin concentrations through effects on renal and hepatic clearance, potentially leading to digoxin toxicity. Horses receiving both medications require regular monitoring of digoxin levels and close observation for signs of toxicity including arrhythmias, anorexia, and depression. Digoxin dose reduction may be necessary when diltiazem is added to the treatment regimen.

Anesthetic agents and sedatives may interact with diltiazem through additive effects on cardiovascular function. Inhalant anesthetics, injectable anesthetic agents, and alpha-2 adrenergic agonist sedatives can all cause cardiovascular depression that may be potentiated by diltiazem. Horses requiring anesthesia or sedation while receiving diltiazem therapy need careful protocol planning and enhanced cardiovascular monitoring. The anesthesiologist should be informed of current diltiazem therapy and recent dosing.

Certain antibiotics and antifungal medications can affect diltiazem metabolism through inhibition of hepatic cytochrome P450 enzymes. Erythromycin, clarithromycin, ketoconazole, and related drugs may increase diltiazem blood levels, potentially enhancing both therapeutic and adverse effects. While the clinical significance of these interactions in horses is not fully characterized, awareness and monitoring are appropriate when such combinations are necessary.

Non-steroidal anti-inflammatory drugs, commonly used in equine practice, may partially counteract the antihypertensive effects of diltiazem through their effects on prostaglandin synthesis and renal function. While this interaction is generally of modest clinical significance, it should be considered in horses receiving both drug classes, particularly those where blood pressure management is a treatment goal.

Administration of diltiazem in horses requires extensive precautions and monitoring protocols to ensure patient safety. The potent effects of this medication on cardiac function mean that careful patient selection, appropriate monitoring, and preparedness for adverse events are essential components of safe therapy. These precautions apply to both acute intravenous treatment and chronic oral administration.

Continuous electrocardiographic monitoring is mandatory during intravenous diltiazem administration. Real-time assessment of heart rate, rhythm, and conduction intervals allows for immediate detection of adverse cardiac effects and guides dose titration. The monitoring equipment should be set up and functioning before medication administration begins, and personnel experienced in ECG interpretation should be present throughout the procedure. Any significant changes in rhythm or conduction should prompt immediate reassessment of the treatment plan.

Blood pressure monitoring is strongly recommended during intravenous diltiazem therapy, as hypotension can occur and may not be immediately apparent from clinical observation alone. Direct arterial blood pressure measurement provides the most accurate assessment, though indirect methods may be acceptable in some situations. Baseline blood pressure should be established before treatment, with frequent measurements during and after drug administration.

Special populations require additional caution when considering diltiazem therapy. Geriatric horses may have reduced hepatic and renal function affecting drug metabolism and clearance, potentially requiring dose adjustments. Horses with underlying liver disease may have altered diltiazem pharmacokinetics and increased risk of adverse effects. Young horses and foals have limited data regarding diltiazem safety and efficacy, and use in these populations should be approached with particular caution.

Competition and performance horses present unique considerations regarding diltiazem use. This medication is likely to be prohibited under most competition rules including FEI, USEF, and racing commission regulations. Detection times may be prolonged, and horses should not compete while receiving diltiazem or until an appropriate withdrawal period has elapsed. Specific withdrawal time recommendations should be obtained from the governing organization and the prescribing veterinarian. Owners and trainers must maintain accurate medication records and understand their responsibilities regarding competition drug rules.

Emergency preparedness is essential whenever diltiazem is administered. Calcium gluconate should be immediately available as it can partially reverse the effects of excessive calcium channel blockade. Other emergency medications and equipment for managing bradycardia, hypotension, and cardiac arrest should be readily accessible. Personnel should be familiar with emergency protocols and prepared to implement them if needed. Horses should remain under observation for an appropriate period following diltiazem administration to ensure stability before returning to their home environment.

Proper storage and handling of diltiazem are essential for maintaining medication stability and ensuring human safety. While the specific requirements may vary somewhat between formulations, general principles apply to all diltiazem products used in equine medicine. Understanding these requirements helps prevent medication degradation and accidental exposures.

Injectable diltiazem solutions should be stored according to manufacturer specifications, typically at controlled room temperature away from light. Most formulations do not require refrigeration, though extreme temperatures should be avoided. The medication should be protected from freezing, which can cause physical changes that affect stability and sterility. Once a vial is opened, unused portions should generally be discarded according to the manufacturer's guidelines for multi-dose containers, or immediately if the product is labeled for single use only. Any discoloration, precipitation, or particulate matter in the solution indicates degradation, and such products should not be used.

Oral formulations including tablets and capsules should be stored in their original containers at room temperature, protected from moisture and light. The tack room or barn may not provide ideal storage conditions, particularly in humid climates or during temperature extremes. Consider storing medications in a climate-controlled area of the home or barn office. Extended-release capsules should not be crushed, broken, or opened, as this destroys the controlled-release mechanism and can result in rapid release of the entire dose.

Safe handling practices protect both humans and animals from unintended diltiazem exposure. Handlers should wash hands thoroughly before and after medication administration. Those administering injectable formulations should use appropriate personal protective equipment and follow proper injection techniques. Accidental human injection or ingestion of diltiazem can cause significant cardiovascular effects and constitutes a medical emergency requiring immediate medical attention. Contact information for human poison control should be readily available.

Expired medications should never be used as stability and potency cannot be guaranteed beyond the labeled expiration date. Disposal should follow local regulations for pharmaceutical waste. Many communities have medication take-back programs or specific disposal guidelines for cardiovascular medications. Flushing medications or placing them in regular trash is generally discouraged due to environmental concerns. Unused medication from horses that have completed treatment or that have been transitioned to different therapy should be properly disposed of rather than saved for potential future use.

While cardiac arrhythmias can affect horses of any breed, certain breed-specific factors may influence the approach to diltiazem therapy. Understanding these considerations helps optimize treatment outcomes and avoid potential complications. The overall principles of diltiazem use remain consistent across breeds, but individual patient factors including breed characteristics should inform treatment decisions.

Draft horses and other large breeds present dosing considerations due to their substantial body mass. These horses may require higher absolute doses to achieve therapeutic drug levels, making accurate weight determination particularly important. The availability of scales at referral centers facilitates precise dosing in these large patients. Draft breeds may also have somewhat different baseline heart rates and cardiovascular parameters compared to lighter breeds, which should be considered when setting treatment goals and interpreting responses to therapy.

Thoroughbreds and other athletic breeds frequently develop atrial fibrillation, making them common candidates for diltiazem therapy. These horses often have well-developed cardiovascular systems adapted to high-level exercise, which may influence their response to rate-controlling medications. Performance goals and competition schedules must be carefully considered when planning treatment, as diltiazem will affect competition eligibility and may require extended withdrawal periods. Return to exercise following treatment for atrial fibrillation requires careful evaluation and gradual reintroduction of work.

Ponies and miniature horses require precise dosing to avoid relative overdose. These smaller equids may be more susceptible to adverse effects at standard weight-based doses, and conservative initial dosing with careful titration is appropriate. The concentrated formulations designed for larger horses must be measured accurately, and dilution may be necessary to achieve appropriate doses for very small patients.

Breed-specific genetic conditions rarely directly impact diltiazem use, but some deserve mention. Quarter Horses and related breeds with hyperkalemic periodic paralysis require careful attention to any medication that might affect electrolyte balance or cardiac function. Friesians have increased prevalence of certain cardiovascular abnormalities including aortic rupture risk, which may influence overall cardiovascular medication decisions. Any breed-specific health conditions should be identified during pre-treatment evaluation and factored into the therapeutic plan.

Regardless of breed, individual patient assessment remains paramount. A thorough cardiovascular workup including physical examination, electrocardiography, and echocardiography should guide treatment decisions. Factors such as age, overall health status, athletic use, and owner goals contribute more significantly to treatment planning than breed alone in most cases.

Several other medications serve similar or complementary roles in managing equine cardiac arrhythmias, and understanding these alternatives helps inform treatment decisions. When diltiazem is not appropriate or insufficient alone, these related medications may offer alternative approaches or be used in combination protocols.

Quinidine remains the most commonly used medication for cardioversion of atrial fibrillation in horses. Unlike diltiazem, which primarily controls rate, quinidine aims to convert the abnormal rhythm back to normal sinus rhythm. The two medications work through different mechanisms and may sometimes be used together, with diltiazem providing rate control while quinidine works to restore normal rhythm. Quinidine carries its own significant risks including potentially serious adverse effects and requires appropriate monitoring and patient selection.

Digoxin is another medication used in horses with atrial fibrillation, particularly for rate control. It slows atrioventricular nodal conduction through different mechanisms than diltiazem and may be used alone or in combination with other rate-controlling agents. The narrow therapeutic index of digoxin requires careful dosing and monitoring. As noted previously, concurrent use with diltiazem can increase digoxin levels, requiring dose adjustment.

Other calcium channel blockers exist but are generally less well-characterized in horses than diltiazem. Verapamil, another non-dihydropyridine calcium channel blocker, has similar effects on cardiac conduction but may have different pharmacokinetic properties in horses. Dihydropyridine calcium channel blockers such as amlodipine have primarily vascular effects rather than cardiac conduction effects and are used for different indications.

Beta-adrenergic blockers represent an alternative approach to rate control in horses with supraventricular arrhythmias. Propranolol and other beta-blockers slow heart rate and atrioventricular conduction through blockade of sympathetic nervous system effects on the heart. These medications may be considered when calcium channel blockers are contraindicated or ineffective, though they carry their own precautions and potential adverse effects.

Complementary therapies including correction of underlying electrolyte imbalances, management of contributing conditions such as infection or inflammation, and supportive care form important components of overall arrhythmia management. No medication should be substituted for another without veterinary guidance, and all cardiac medications require appropriate monitoring and follow-up. The choice among available options depends on the specific arrhythmia, underlying cardiac status, patient factors, and treatment goals.